Statistics

Tobira Therapeutics | CVC for NASH | CENTAUR study

www.tobiratherapeutics.com/

Tobira is currently enrolling patients in CENTAUR, a global randomized Phase 2 study of CVC vs placebo in patients with NASH and liver fibrosis. For more ...

Tobiratherapeutics.com

Domain is redirected to: Tobiratx.com

Conversion Technology Metas Server

Tobiratherapeutics.com is hosted in United States / Baltimore . Tobiratherapeutics.com doesn't use HTTPS protocol. Number of used technologies: 5. First technologies: CSS, Html, Html5, Number of used javascripts: 8. First javascripts: Respond.min.js, Prototype.js, Scriptaculous.js, Number of used analytics tools: 1. First analytics tools: Google Analytics, Its server type is: Microsoft-IIS/7.5.

Technologies in use by Tobiratherapeutics.com

Technology

Number of occurences: 5

CSS
Html
Html5
Javascript
jQuery

Javascripts

Number of occurences: 8

respond.min.js
prototype.js
scriptaculous.js
jquery.js
bootstrap.min.js
cookie.js
cms.js
navigation.js

Analytics

Number of occurences: 1

Google Analytics

Server Type

Microsoft-IIS/7.5

Google Analytics ID

UA-51514319-1

Conversion rate optimization
Clickable call number	Not founded!
Conversion form (contact form, subcriber)	Not founded!
Clickable email	Founded!
CTA (call to action) button	Founded!
List	Founded!
Image	Not founded!
Enhancement	Not founded!
Responsive website	Founded!
Facebook sharing	Not founded!
Google+ sharing	Not founded!
Twitter sharing	Not founded!
Linkedin sharing	Not founded!
Blog on the webiste	Not founded!

HTTPS (SSL) - Tobiratherapeutics.com

Missing HTTPS protocol.

Meta - Tobiratherapeutics.com

Number of occurences: 4

Name:
Content: IE=edge
Name: description
Content: Tobira is currently enrolling patients in CENTAUR, a global randomized Phase 2 study of CVC vs placebo in patients with NASH and liver fibrosis. For more information about the CENTAUR study, visit www.clinicaltrials.gov, trial identifier NCT02217475.
Name: keywords
Content: cenicriviroc, CVC, non-alcoholic steatohepatitis, NASH, HIV-1, human immunodeficiency virus, fibrosis, inflammation Tobira Therapeutics, CENTAUR study, NASH study, Tobira study
Name: viewport
Content: width=device-width, initial-scale=1.0

Server / Hosting

IP: 69.63.140.80
Latitude: 39.28
Longitude: -76.56
Country: United States
City: Baltimore

Rname

b.ns.zerigo.net
d.ns.zerigo.net
e.ns.zerigo.net
c.ns.zerigo.net
f.ns.zerigo.net
a.ns.zerigo.net
tobiratherapeutics-com.mail.protection.outlook.com

Target

hostmaster.zerigo.com

HTTP Header Response

HTTP/1.1 301 Moved Permanently Cache-Control: no-cache Pragma: no-cache Transfer-Encoding: chunked Content-Type: text/html; charset=UTF-8 Location: http://www.tobiratx.com Server: Microsoft-IIS/7.5 Date: Sun, 10 Apr 2016 16:12:18 GMT HTTP/1.1 200 OK Transfer-Encoding: chunked Content-Type: text/html; charset=UTF-8 Server: Microsoft-IIS/7.5 Set-Cookie: CFID=22940218;path=/ Set-Cookie: CFTOKEN=f634e4281957318a%2D095D9780%2DBC30%2D5BEC%2D2DB14424DA230E8D;path=/ Set-Cookie: CFAUTHORIZATION_tobira=;expires=Fri, 10-Apr-2015 16:12:19 GMT;path=/ Date: Sun, 10 Apr 2016 16:12:18 GMT